After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
The event is expected to bring together health and wellness enthusiasts for an afternoon of insights, learning and practical takeaways
CDMO strengthens global quality framework through digital transformation, AI-enabled investigations, workforce development and continuous audit readiness
Initiative conducted in association with IMA Charitable Blood Centre promotes voluntary blood donation and community awareness on life-saving transfusions
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
